

03 October 2022

Biologic medicines in Dermatology

Request and Response

How many patients were treated in the last 3 months by the **Dermatology** department (for any medical condition) with the following biologic drugs:

• Abatacept	<5
• Adalimumab – Humira	45
• Adalimumab Biosimilar	176
• Apremilast	9
• Bimekizumab	<5
• Brodalumab	<5
• Certolizumab	<5
• Dimethyl fumarate	<5
• Etanercept – Enbrel	<5
• Etanercept Biosimilar	9
• Golimumab	<5
• Guselkumab	85
• Infliximab – Remicade	5
• Infliximab Biosimilar	10
• Ixekizumab	48
• Risankizumab	65
• Secukinumab	37
• Tildrakizumab	6
• Tofacitinib	<5
• Ustekinumab	80
• Upadacitinib	9

We are unable to provide an exact figure where numbers are very low. This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act as this could make staff personally identifiable. This would be unfair to the individuals to release this information. Disclosure would constitute a breach of the principles of the Data Protection Act 2018.